NRIX NURIX THERAPEUTICS
Health Care · Russell 2000
Next earnings: Thu 28 Jan 2027 · estimated
What 16 analyst firms say about NURIX THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
14 rated views · 17 analyst/firm records · 16 firms
Radar score
- Russell 2000 · Top Picks · 6MStrong · #8 in the index93
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8069
Recent analyst activity · last 90 days
Our tracked history has 11 reports on NRIX from 10 analyst firms in the last 90 days (16 firms in the past year).
Comparing each firm's latest target with its previous one: 4 raised their price target, 3 lowered it and 2 left it unchanged.
Ratings, latest available report against the previous one: 0 upgrades and 1 downgrade.
Latest observed target change: Wells Fargo lowered its target from $25.00 (set 8 Jun 2026) to $20.00 on 4 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Baird | Brian P Skorney | Buy | 13 Oct 2026 | 36.00 USD |
| Baird | Joel Beatty | Buy | 13 Oct 2026 | 36.00 USD |
| BTIG | Jeet Mukherjee | Buy | 10 Jul 2026 | 32.00 USD |
| H.C. Wainwright | Robert Burns | Buy | 16 Oct 2026 | 36.00 USD |
| Jefferies | Roger Song | Buy | 8 Jun 2026 | 45.00 USD |
| Mizuho | Joseph Catanzaro | Buy | 13 Jul 2026 | 34.00 USD |
| Morgan Stanley | Terence Flynn | Buy | 28 Jul 2026 | 38.00 USD |
| Needham | Gil Blum | Buy | 13 Oct 2026 | 34.00 USD |
| Oppenheimer | Kostas Biliouris | Buy | 13 Oct 2026 | 32.00 USD |
| Piper Sandler | Biren Amin | Buy | 12 Oct 2026 | 35.00 USD |
| RBC Capital Markets | Brian Abrahams | Buy | 13 Oct 2026 | 35.00 USD |
| Stifel | Stephen Willey | — | 13 Oct 2026 | 41.00 USD |
| Truist | Gregory Renza | Buy | 13 Oct 2026 | 33.00 USD |
| UBS | David Dai | Buy | 22 Jul 2026 | 31.00 USD |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Wells Fargo | Derek Archila | ConflictConflicting reports · excluded | 8 Jun 2026 | 25.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 05:50 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.